From: An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients
Study | Patients | LMWH | UFH | Safety |
---|---|---|---|---|
Harenberg et al.1990 [30] | 166 | Dalteparin 1500 aPTT units s.c. o.d. | 5000 IU s.c. t.i.d. | Similar incidence of adverse events in both groups. Haematomas were significantly smaller in diameter in the LMWH group |
Bergmann and Neuhart, 1996 [31] | 439 | Enoxaparin 20 mg s.c. o.d. | 5000 IU s.c. b.i.d. | Similar incidence of adverse events in both groups |
Lechler et al. 1996 [32] | 959 | Enoxaparin 40 mg s.c. o.d. | 5000 IU s.c. t.i.d. | Fewer major bleeding complications and significantly fewer injection-site haematomas (>5 cm diameter) in the enoxaparin group |
Harenberg et al. 1996 [33] | 1,968 | Nadroparin 36 mg s.c. o.d. | 5000 IU s.c. t.i.d. | Major bleeding was rare. Local haematomas (>2.5 cm diameter), local erythema and local allergic reactions were more frequent in the UFH group. |
Kleber et al. 2003 [34] | 665 | Enoxaparin 40 mg s.c. o.d. | 5000 IU s.c. t.i.d. | Significantly fewer adverse events in the enoxaparin group |